Stock Track | Immunocore Holdings Soars 5.17% as Earnings Beat Expectations on Strong KIMMTRAK Sales

Stock Track

26 Feb

Immunocore Holdings plc0.00%Post-market

Immunocore Holdings plc (IMCR), a commercial-stage biotechnology company, saw its stock soar 5.17% in intraday trading on Wednesday, February 26, 2025. The surge followed the company's impressive fourth quarter and full-year 2024 financial results, driven by strong sales of its lead product, KIMMTRAK.

The key highlights from Immunocore's earnings report include:

KIMMTRAK net sales of $84.1 million for Q4 2024 and $310.0 million for the full year, marking 11 consecutive quarters of revenue growth since its launch.
Progress in expanding KIMMTRAK's indications, with enrollment ongoing in two Phase 3 trials (TEBE-AM and ATOM) for additional melanoma indications.
Advancement of the PRAME portfolio, with the first patient randomized in the Phase 3 PRISM-MEL-301 trial for brenetafusp in first-line advanced cutaneous melanoma.
Initiation of Phase 1 trials for IMC-P115C (PRAME-A02) and IMC-R117C (PIWIL1), targeting additional cancer types.
Cash, cash equivalents, and marketable securities of $820.4 million as of December 31, 2024, providing a strong financial position.

Immunocore's CEO, Bahija Jallal, expressed confidence in the company's growth prospects, citing the continued execution of KIMMTRAK's lifecycle management program, advancement of the clinical pipeline, and expansion into autoimmune diseases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

no data

No relevant data is available

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1191083799"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191083799\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1191083799?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 00:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191083799","market":"us","top_or_hot":-1,"title":"Stock Track | Immunocore Holdings Soars 5.17% as Earnings Beat Expectations on Strong KIMMTRAK Sales","media":"Stock Track","content":"<p>Immunocore Holdings plc (IMCR), a commercial-stage biotechnology company, saw its stock soar 5.17% in intraday trading on Wednesday, February 26, 2025. The surge followed the company's impressive fourth quarter and full-year 2024 financial results, driven by strong sales of its lead product, KIMMTRAK.</p>\n\n<p>The key highlights from Immunocore's earnings report include:</p>\n\n<ul>\n<li>KIMMTRAK net sales of $84.1 million for Q4 2024 and $310.0 million for the full year, marking 11 consecutive quarters of revenue growth since its launch.</li>\n<li>Progress in expanding KIMMTRAK's indications, with enrollment ongoing in two Phase 3 trials (TEBE-AM and ATOM) for additional melanoma indications.</li>\n<li>Advancement of the PRAME portfolio, with the first patient randomized in the Phase 3 PRISM-MEL-301 trial for brenetafusp in first-line advanced cutaneous melanoma.</li>\n<li>Initiation of Phase 1 trials for IMC-P115C (PRAME-A02) and IMC-R117C (PIWIL1), targeting additional cancer types.</li>\n<li>Cash, cash equivalents, and marketable securities of $820.4 million as of December 31, 2024, providing a strong financial position.</li>\n</ul>\n\n<p>Immunocore's CEO, Bahija Jallal, expressed confidence in the company's growth prospects, citing the continued execution of KIMMTRAK's lifecycle management program, advancement of the clinical pipeline, and expansion into autoimmune diseases.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Immunocore Holdings Soars 5.17% as Earnings Beat Expectations on Strong KIMMTRAK Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Immunocore Holdings Soars 5.17% as Earnings Beat Expectations on Strong KIMMTRAK Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-27 00:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Immunocore Holdings plc (IMCR), a commercial-stage biotechnology company, saw its stock soar 5.17% in intraday trading on Wednesday, February 26, 2025. The surge followed the company's impressive fourth quarter and full-year 2024 financial results, driven by strong sales of its lead product, KIMMTRAK.</p>\n\n<p>The key highlights from Immunocore's earnings report include:</p>\n\n<ul>\n<li>KIMMTRAK net sales of $84.1 million for Q4 2024 and $310.0 million for the full year, marking 11 consecutive quarters of revenue growth since its launch.</li>\n<li>Progress in expanding KIMMTRAK's indications, with enrollment ongoing in two Phase 3 trials (TEBE-AM and ATOM) for additional melanoma indications.</li>\n<li>Advancement of the PRAME portfolio, with the first patient randomized in the Phase 3 PRISM-MEL-301 trial for brenetafusp in first-line advanced cutaneous melanoma.</li>\n<li>Initiation of Phase 1 trials for IMC-P115C (PRAME-A02) and IMC-R117C (PIWIL1), targeting additional cancer types.</li>\n<li>Cash, cash equivalents, and marketable securities of $820.4 million as of December 31, 2024, providing a strong financial position.</li>\n</ul>\n\n<p>Immunocore's CEO, Bahija Jallal, expressed confidence in the company's growth prospects, citing the continued execution of KIMMTRAK's lifecycle management program, advancement of the clinical pipeline, and expansion into autoimmune diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMCR","symbol_name":"Immunocore Holdings plc","start_time":0,"source_url":"","article_id":"1191083799","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191083799","pubTimestamp":1740587685,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Immunocore Holdings plc , a commercial-stage biotechnology company, saw its stock soar 5.17% in intraday trading on Wednesday, February 26, 2025. The surge followed the company's impressive fourth quarter and full-year 2024 financial results, driven by strong sales of its lead product, KIMMTRAK.The key highlights from Immunocore's earnings report include:. KIMMTRAK net sales of $84.1 million for Q4 2024 and $310.0 million for the full year, marking 11 consecutive quarters of revenue growth since","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMCR":"Immunocore Holdings plc"},"translate_title":"股票轨迹Immunocore Holdings飙升5.17%，KIMMTRAK销售强劲，盈利超出预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMCR":1},"content_text":"Immunocore Holdings plc (IMCR), a commercial-stage biotechnology company, saw its stock soar 5.17% in intraday trading on Wednesday, February 26, 2025. The surge followed the company's impressive fourth quarter and full-year 2024 financial results, driven by strong sales of its lead product, KIMMTRAK.\nThe key highlights from Immunocore's earnings report include:\n\nKIMMTRAK net sales of $84.1 million for Q4 2024 and $310.0 million for the full year, marking 11 consecutive quarters of revenue growth since its launch.\nProgress in expanding KIMMTRAK's indications, with enrollment ongoing in two Phase 3 trials (TEBE-AM and ATOM) for additional melanoma indications.\nAdvancement of the PRAME portfolio, with the first patient randomized in the Phase 3 PRISM-MEL-301 trial for brenetafusp in first-line advanced cutaneous melanoma.\nInitiation of Phase 1 trials for IMC-P115C (PRAME-A02) and IMC-R117C (PIWIL1), targeting additional cancer types.\nCash, cash equivalents, and marketable securities of $820.4 million as of December 31, 2024, providing a strong financial position.\n\nImmunocore's CEO, Bahija Jallal, expressed confidence in the company's growth prospects, citing the continued execution of KIMMTRAK's lifecycle management program, advancement of the clinical pipeline, and expansion into autoimmune diseases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."

Consult now
Download APP
Scan QR code to download the app.